News Sentiment

PRQR sentiment intelligence

ProQR Therapeutics BV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.73 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.4% over one week, +20.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

[EFFECT] ProQR Therapeutics N.V. SEC Filing

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -4.4% Price reacting lower
Trend fit Trend inactive 20.1% over four weeks
Fair value -13.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 7
TradingView 6
MT Newswires 3
MarketBeat 2
GuruFocus 2
Sahm 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 14
Analyst action 6
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Stock Titan Direct company coverage

ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet

ProQR Therapeutics N.V. is registering for resale up to 3,030,303 ordinary shares previously issued to a selling shareholder under an April 7, 2026 Share Purchase Agreement. The company states it will not receive any proceeds from this offering. ProQR is a clinical-stage biotechn

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 21:12
Source
Stock Titan
Stock Titan Direct company coverage

Aescap group and Patrick Krol report ProQR (PRQR) shareholdings

Aescap group and Patrick Krol have filed a Schedule 13G/A, disclosing their shareholdings in ProQR Therapeutics N.V. The filing indicates that Aescap Life Sciences, Aescap Genetics, Inspirational Visions, and Patrick Krol himself hold varying percentages of ProQR's ordinary share

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 15:40
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] ProQR Therapeutics N.V. Insider Trading Activity

The article reports on an insider trading activity at ProQR Therapeutics N.V., where CEO Daniel Anton de Boer purchased 150,000 ordinary shares for $1.74 each on July 9, 2026, totaling $261,000. This transaction increased his direct holdings to 300,000 ordinary shares. The Form 4

Tone
Positive 70/100
Event
Market update
Published
13 Jul 2026 12:10
Source
Stock Titan
MarketBeat Direct company coverage

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a "Moderate Buy" consensus recommendation from seven brokerages, with an average 12-month price target of $7.33, despite mixed individual ratings. Recent adjustments include target cuts by Chardan Capital and JonesTrading, and do

Tone
Neutral 50/100
Event
Analyst action
Published
10 Jul 2026 06:09
Source
MarketBeat
GuruFocus Direct company coverage

Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV

ProQR Therapeutics NV CEO de Boer Daniel Anton recently purchased 150,000 shares of the company, increasing his total holdings to 150,000 shares. This transaction signals insider confidence, with no insider sells reported in the past year. The stock, currently trading at $1.59, a

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 23:10
Source
GuruFocus
Stock Titan Direct company coverage

ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59

ProQR Therapeutics N.V. CEO Daniel Anton de Boer purchased 150,000 Ordinary Shares of the company at $1.59 per share on July 7, 2026, in an open-market transaction. This purchase established his direct ownership of 150,000 Ordinary Shares. The filing indicates a positive sentimen

Tone
Positive 86/100
Event
Market update
Published
08 Jul 2026 18:55
Source
Stock Titan
scanx.trade Direct company coverage

ProQR Therapeutics files prospectus for 3.03M share offering

ProQR Therapeutics has filed a prospectus for the offering of 3.03 million ordinary shares, to be sold by an existing shareholder. The company will not receive any proceeds from this sale. The offering's pricing and timing will be determined later and are subject to market condit

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 03:10
Source
scanx.trade
Stock Titan Direct company coverage

ProQR Therapeutics (PRQR) registers 3.03M shares for resale on Nasdaq

ProQR Therapeutics N.V. (PRQR) has filed a Form F-3 shelf prospectus to register for resale up to 3,030,303 ordinary shares held by a selling shareholder, Ginkgo Bioworks Holdings, Inc. ProQR will not receive any proceeds from these resales, as the shares were issued to Ginkgo Ho

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:10
Source
Stock Titan
Seeking Alpha Direct company coverage

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR)

ProQR Therapeutics (PRQR) has advanced its RNA editing platform, demonstrating human pharmacological activity with AX-0810’s Phase 1 data. The company is strategically focusing on NTCP modulation for rare pediatric liver disease (biliary atresia) to achieve quicker clinical valid

Tone
Positive 75/100
Event
Market update
Published
04 Jul 2026 15:09
Source
Seeking Alpha
MSN Direct company coverage

ProQR posts early-stage trial data for liver disease candidate

ProQR Therapeutics has released early-stage trial data for its investigational liver disease candidate. This initial data provides insight into the drug's performance and safety profile in its early developmental phases. Further details from the trial data were not immediately av

Tone
Positive 68/100
Event
Regulatory and legal
Published
02 Jul 2026 23:40
Source
MSN
Sahm Direct company coverage

Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought €231k Of Shares

ProQR Therapeutics' Independent Non-Executive Director, Bart Filius, recently purchased US$231k worth of the company's shares at US$1.54 each. While the company recorded a loss last year, this insider buying, although at a lower price than the current US$1.75, along with past ins

Tone
Positive 67/100
Event
Market update
Published
02 Jul 2026 19:12
Source
Sahm
Finviz Direct company coverage

PRQR - ProQR Therapeutics N.V Options

This article provides an overview of ProQR Therapeutics N.V. (PRQR) stock information as of July 2, 2026, including its last close price, daily change, and various financial metrics. It details key statistics such as market capitalization, earnings per share, sales performance, i

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 18:12
Source
Finviz
Investing.com South Africa Direct company coverage

Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com

This article announces the filing of Form 13D/A for ProQR Therapeutics N.V. for the period ending June 30th. It is a brief announcement from Investing.com, accompanied by a Reuters image and a ticker for PRQR stock performance.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 17:12
Source
Investing.com South Africa
Stock Titan Direct company coverage

Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances

The Van Herk group has filed an updated Schedule 13D/A, reporting a 10.9% beneficial ownership in ProQR Therapeutics N.V. (PRQR), holding 15,384,250 ordinary shares. This change in percentage is solely due to an increase in ProQR's total shares outstanding following recent issuan

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 07:40
Source
Stock Titan
TradingView Direct company coverage

ProQR Therapeutics N.V. Actuals & Estimates (TRADEGATE:0PQ)

This article provides financial actuals and estimates for ProQR Therapeutics N.V. (0PQ) traded on the Tradegate Exchange. It details expert forecasts including maximum and minimum price estimates, historical stock performance, and upcoming earnings report dates. The company's rec

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 05:39
Source
TradingView
Stock Titan Direct company coverage

Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market

ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares in an open-market transaction on June 26, 2026, at a price of $1.54 per share. This transaction, detailed in a Form 4 SEC filing, increases his direct holdings in ProQR to 150,000 Ordinary Shares, indi

Tone
Positive 73/100
Event
Market update
Published
01 Jul 2026 04:40
Source
Stock Titan
Stock Titan Direct company coverage

ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike

A director at ProQR Therapeutics N.V. (PRQR), Hinsch Gylvin Lykke, received a grant of 14,595 share options with an exercise price of $1.42 per share. These options, granted on June 2, 2026, will vest 25% on June 2, 2027, with the remainder vesting in quarterly installments over

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:40
Source
Stock Titan
TradingView Direct company coverage

0PQ Forecast — Price Target — Prediction for 2027

This article provides a forecast for ProQR Therapeutics N.V. (0PQ) stock, including analyst price targets and ratings. It details quarterly and annual financial metrics such as EPS, revenue, and net income, along with historical stock performance. The piece also addresses frequen

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of ProQR Therapeutics N.V. – LS:A12B97

This article displays the "Price to sales forward" financial metric for ProQR Therapeutics N.V. (LS:A12B97). It indicates that for the specified period, the value is "No trades," meaning no data is currently available for this metric. The article is largely a financial data stub

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:40
Source
TradingView
Stock Titan Direct company coverage

ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares

ProQR Therapeutics is conducting a public offering of 27,624,310 ordinary shares at $1.81 per share, while Eli Lilly and Company will concurrently purchase 5,100,780 shares in a private placement at the same price. The combined offerings are expected to generate approximately $55

Tone
Positive 63/100
Event
Balance sheet
Published
26 Jun 2026 18:39
Source
Stock Titan
Sahm Direct company coverage

Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success

ProQR Therapeutics reported positive early-stage clinical data for its RNA editing therapy AX-0810, which demonstrated strong target engagement for cholestatic liver diseases. Concurrently, the company announced a $50 million underwritten offering, with Eli Lilly and Co. investin

Tone
Positive 71/100
Event
Analyst action
Published
26 Jun 2026 16:41
Source
Sahm
TradingView Direct company coverage

ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR)

This article provides an overview of ProQR Therapeutics N.V. (NASDAQ:PRQR) stock, including its current price, performance history, and analyst forecasts. It also delves into the company's financial actuals and estimates, covering income, balance sheet, cash flow, and valuation m

Tone
Negative 34/100
Event
Analyst action
Published
26 Jun 2026 13:39
Source
TradingView
marketscreener.com Direct company coverage

Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating

Chardan Research has lowered its price target for ProQR Therapeutics (PRQR) to $3 from $4 but has maintained a Buy rating on the stock. This adjustment comes after the company announced positive Phase 1 target engagement data for its AX-0810 program and provided updates on its NT

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 12:39
Source
marketscreener.com
Stock Titan Direct company coverage

ProQR (PRQR) prices share offering and Eli Lilly private placement

ProQR Therapeutics announced an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, aiming to raise approximately $46.5 million in net proceeds. Concurrently, the company will sell 5,100,780 additional shares to Eli Lilly in a private placeme

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:39
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of ProQR Therapeutics N.V. – NASDAQ:PRQR

This article focuses on the "Price to book forward" metric for ProQR Therapeutics N.V. (NASDAQ: PRQR). It appears to be a stub or a section from a larger financial data platform, providing a title but no actual data or analysis other than indicating the company and the metric.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 08:39
Source
TradingView
Moomoo Direct company coverage

ProQR Therapeutics NV - to Use Proceeds for R

This article announces that ProQR Therapeutics NV plans to utilize the proceeds from a recent event or offering to fund its research and development initiatives.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 03:40
Source
Moomoo